SER130

Preclinical phase

Phase i

Phase ii a

Phase ii b

Phase iii

Approved

SER130 is a potent interleukin-4 (IL-4) agonist.

Diabetes causes a number of metabolic and physiological abnormalities in the retina. Substantial evidence suggest that inflammation is a non-specific response to the changes in the eyes blood vessels caused by elevated blood glucose, hyperglycemia. Studies have shown that various inflammatory cytokines are involved in the development of clinically recognised lesions of diabetic retinopathy. 

Levels of cytokine and chemokine are increased in the retina and are believed to contribute to the degeneration of the retina. Various anti-inflammatory compounds have shown beneficial effect in diabetic retinopathy.

The small peptide, SER130, is an interleukin-4 (IL-4) receptor agonist. SER130 is derived from the human IL-4 protein. It has shown potent anti-inflammatory effects in various pre-clinical inflammation test models.

SER130 is believed to be able to stop the inflammation involved in diabetic retinopathy whereby stopping the progression of the disease.